GO:0051630 acetylcholine uptake: Genes, Functions, Methods

Acetylcholine (ACh) is one of the most extensively studied neurotransmitters, acting as a major neuromodulator in the central and peripheral nervous systems and as a paracrine signal in various non-neural tissues. The Gene Ontology term GO:0051630, acetylcholine uptake, refers to the directed movement of acetylcholine into a cell, typically presynaptic neurons or glial cells. This process is fundamental to cholinergic signaling because it regulates the availability of ACh for subsequent release, degradation, or intracellular actions. Understanding acetylcholine uptake is critical for researchers studying synaptic transmission, neurodegenerative diseases, and non-neuronal cholinergic systems. The concept of acetylcholine uptake emerged from early biochemical studies demonstrating that rat brain cortex slices can accumulate exogenous acetylcholine. Subsequent work established that choline uptake is tightly coupled to acetylcholine synthesis and release, and that acetylcholine itself can be taken up by cells through mechanisms that are distinct from choline transport. More recent investigations have shown that acetylcholinesterase inhibition augments endogenous acetylcholine uptake and enhances cholinergic facilitation of hippocampal long-term potentiation, suggesting that uptake is dynamically regulated during synaptic plasticity. Despite decades of research, the molecular identity of the acetylcholine uptake transporter remains incompletely defined. The central cholinergic synapse relies on a suite of proteins including the high-affinity choline transporter CHT1 (SLC5A7), the vesicular acetylcholine transporter VAChT (SLC18A3), and acetylcholinesterase (AChE). Acetylcholine uptake has also been described in non-neuronal contexts, such as spleen fibroblastic reticular cells where ACh promotes lipid metabolism to drive autoreactive B cell responses, and in pancreatic islets where acetylcholine-induced insulin release depends on calcium uptake. These findings underscore the broad biological significance of GO:0051630.

GO:0051630 acetylcholine uptake is defined as the directed movement of acetylcholine into a cell, typically presynaptic neurons or glial cells. Acetylcholine is a major neurotransmitter and neuromodulator both in the central and peripheral nervous systems, and it also acts as a paracrine signal in various non-neural tissues. The synonym acetylcholine import is sometimes used interchangeably. This biological process encompasses the transport of acetylcholine across the plasma membrane, which may occur via specific transporters or through mechanisms coupled to choline uptake and acetylcholinesterase activity.

Acetylcholine uptake is important because it controls the concentration and duration of acetylcholine available for signaling at synapses and in non-neuronal tissues. Dysregulation of cholinergic transmission is a hallmark of Alzheimer's disease, where targeting the cholinergic system remains a mainstay of symptomatic therapy. In the hippocampus, inhibition of acetylcholinesterase augments endogenous acetylcholine uptake and facilitates long-term potentiation, directly linking uptake to learning and memory mechanisms. Beyond the nervous system, acetylcholine uptake and signaling influence insulin secretion from pancreatic islets, catecholamine uptake in adrenal chromaffin cells, and immune responses in the spleen. Thus, GO:0051630 sits at the intersection of neuroscience, endocrinology, and immunology.

The following genes and proteins have been implicated in acetylcholine uptake, cholinergic signaling, or related transport processes based on published literature.

Acetylcholine uptake is regulated at multiple levels. Acetylcholinesterase (AChE) activity controls the concentration of ACh available for transport; inhibition of AChE augments endogenous ACh uptake and facilitates hippocampal long-term potentiation. Choline uptake via CHT1 (SLC5A7) is the rate-limiting step for ACh synthesis and is tightly coupled to ACh release, indirectly influencing ACh uptake. Muscarinic autoreceptors such as CHRM2 provide feedback inhibition of ACh release, which may affect the pool available for uptake. In non-neuronal tissues, acetylcholine uptake and signaling are modulated by local factors; for example, in pancreatic islets, ACh-induced insulin release depends on calcium uptake, and in adrenal chromaffin cells, ACh inhibits catecholamine uptake. Spleen fibroblastic reticular cell-derived ACh promotes lipid metabolism to drive autoreactive B cell responses, indicating that immune signals can regulate ACh availability and uptake. Overall, regulation of GO:0051630 is intertwined with cholinergic activity, calcium signaling, and metabolic state.

Alzheimer's disease is characterized by progressive loss of cholinergic neurons in the basal forebrain, leading to reduced acetylcholine synthesis, release, and uptake. Targeting the cholinergic system remains a primary symptomatic treatment strategy, with acetylcholinesterase inhibitors such as donepezil, rivastigmine, and galantamine used to boost ACh levels. Because AChE inhibition augments endogenous acetylcholine uptake and facilitates hippocampal long-term potentiation, understanding GO:0051630 may inform new therapeutic approaches. The central cholinergic synapse primer highlights that CHT1, VAChT, and AChE are core components of the cholinergic machinery that is disrupted in Alzheimer's disease.

Acetylcholine signaling plays a role in insulin secretion from pancreatic islets. In rat pancreatic islets, acetylcholine-induced insulin release depends on Ca++ uptake, linking cholinergic activity to glucose homeostasis. Dysregulation of ACh uptake or signaling could contribute to type 2 diabetes and other metabolic disorders. Additionally, spleen fibroblastic reticular cell-derived acetylcholine promotes lipid metabolism to drive autoreactive B cell responses, connecting ACh to immune-metabolic crosstalk. These findings suggest that GO:0051630 is relevant beyond the nervous system and may be a target for modulating endocrine and metabolic functions.

Non-neuronal acetylcholine acts as a paracrine signal in immune tissues. In the spleen, fibroblastic reticular cells produce acetylcholine that promotes lipid metabolism and drives autoreactive B cell responses, implicating ACh uptake in autoimmune or inflammatory conditions. Cholinergic signaling via nicotinic receptors such as CHRNA7 modulates cytokine production and inflammation. Therefore, dysregulation of acetylcholine uptake could contribute to immune dysregulation, and targeting GO:0051630 may offer therapeutic opportunities in inflammatory diseases.

In adrenal chromaffin cells, acetylcholine inhibits catecholamine uptake, indicating cross-talk between cholinergic and adrenergic systems. This interaction is important for stress responses and could be relevant to disorders such as pheochromocytoma or adrenal insufficiency. Understanding how ACh uptake influences catecholamine handling may provide insights into stress-related pathologies and adrenal function.

Radiolabeled acetylcholine or choline uptake assays are classic methods to measure GO:0051630. In early studies, rat brain cortex slices were incubated with [3H]acetylcholine to quantify uptake. Similar assays can be adapted to cell lines with CRISPR-modified genes to test the role of candidate transporters. These assays measure saturable, temperature-dependent uptake and can be combined with inhibitors to distinguish specific from nonspecific transport.

Electrophysiological recordings in hippocampal slices can measure long-term potentiation (LTP) as a functional readout of cholinergic signaling. Acetylcholinesterase inhibition augments endogenous acetylcholine uptake and facilitates LTP, providing a direct link between uptake and synaptic plasticity. Field potential recordings combined with pharmacological manipulation of AChE or cholinergic receptors can reveal how GO:0051630 influences circuit function.

In pancreatic islets, acetylcholine-induced insulin release depends on Ca++ uptake, which can be measured using calcium imaging and insulin secretion assays. These methods can be applied to CRISPR-engineered islet cell lines to test the role of candidate ACh transporters or receptors. Similarly, in adrenal chromaffin cells, catecholamine uptake and release can be monitored to study cross-talk with cholinergic signaling.

Genome-wide CRISPR knockout or activation screens can identify genes that regulate acetylcholine uptake. By coupling uptake assays with next-generation sequencing, researchers can discover novel transporters or regulators. Transcriptomic profiling of cholinergic tissues or immune cells can reveal expression patterns of candidate genes such as SLC5A7, SLC18A3, and ACHE. These approaches are powerful for uncovering the molecular machinery of GO:0051630.

Researchers studying acetylcholine uptake-related genes often need to determine whether a candidate gene is causally involved in the transport process, how mutations affect protein function, and whether modulating gene expression alters cholinergic signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and reproducibility.

GO:0051630 acetylcholine uptake is a fundamental biological process that regulates the availability of acetylcholine for neurotransmission, neuromodulation, and paracrine signaling. Despite decades of research, the molecular identity of the acetylcholine transporter remains incompletely understood, and the process is tightly intertwined with choline uptake, acetylcholinesterase activity, and cholinergic receptor signaling. Its relevance extends from synaptic plasticity and Alzheimer's disease to insulin secretion, adrenal function, and immune regulation. Researchers can leverage CRISPR-based knockout, point mutation, knock-in, and overexpression models to dissect the genetic and molecular basis of acetylcholine uptake. EDITGENE offers end-to-end services, from custom cell model generation to CRISPR library screening and bioinformatics, to accelerate discoveries in cholinergic biology and related diseases.